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Abstract
Pentosan polysulfate (PPS), a heparinoid compound essentially devoid of anticoagulant activity,
modulates cell growth and decreases inflammation. We investigated the effect of PPS on the
progression of established atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits.
After severe atherosclerosis developed on an atherogenic diet, WHHL rabbits were treated with
oral PPS or tap water for 1 month. The aortic intima-to-media ratio and macrophage infiltration
were reduced, plaque collagen content was increased, and plaque fibrous caps were preserved by
PPS treatment. Plasma lipid levels and post-heparin hepatic lipase activity remained unchanged.
However, net collagenolytic activity in aortic extracts was decreased, and the levels of matrix
metalloproteinase (MMP)-2 and tissue inhibitor of metalloproteinase (TIMP) activity were
increased by PPS. Moreover, PPS treatment decreased tumor necrosis factor α (TNFα)-stimulated
proinflammatory responses, in particular activation of nuclear factor-κB and p38, and activation of
MMPs in macrophages. In conclusion, oral PPS treatment prevents progression of established
atherosclerosis in WHHL rabbits. This effect may be partially mediated by increased MMP-2 and
TIMP activities in the aortic wall and reduced TNFα-stimulated inflammation and MMP
activation in macrophages. Thus, PPS may be a useful agent in inhibiting the progression of
atherosclerosis.
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Heparin and heparin-like molecules decrease cell proliferation, increase net extracellular
matrix production in several cell types, and decrease the secretion of matrix
metalloproteinases (MMPs) in vitro.1–4 The accumulation of macrophage-derived foam cells
in atherosclerotic plaques correlates with increased release of tumor necrosis factor α
(TNFα) and MMPs,5,6 which may influence vascular remodeling and plaque rupture, thus
precipitating acute complications such as unstable angina and acute myocardial
infarction.7–11
Pentosan polysulfate (PPS) is an oral heparinoid-like preparation essentially devoid of
anticoagulant activity and is approved for the treatment of interstitial cystitis.12 We
previously found that PPS treatment prevents the development of chronic inflammatory
lesions and histological lesions in 5/6 nephrectomized rats.13 We also found that PPS
decreases mesangial cell proliferation in vitro,14 human vascular smooth muscle cells
derived from vascular grafts,15 and smooth muscle cells obtained from the prostate inter-
stitium.16 In addition, PPS increases MMP-2 secretion and stimulates the production of
tissue inhibitor of metalloproteinase (TIMP)-1 and the shedding of TIMP-3 from the surface
of mesangial cells.14
In this study, we investigated the effect of oral treatment with PPS on the progression of
established atherosclerotic lesions in Watanabe heritable hyperlipidemic (WHHL) rabbits.17
We examined the effect of PPS on established atherosclerotic lesions as the most clinically
relevant and the most stringent test of PPS efficacy.
MATERIALS AND METHODS
Reagents
PPS was from IVAX Corp. (Miami, FL, USA) or SWATI Spentose (Mumbai, India), tissue
culture reagents were from Gibco BRL (Grand Island, NY, USA), 10% gelatin
polyacrylamide zymography gels from Novex (San Diego, CA, USA), the First Strand
cDNA synthesis kit from Boehringer Mannheim (Indianapolis, IN, USA), and other reagents
were from Sigma Chemical (St Louis, MO, USA).
Study Protocol
The 3-month-old female WHHL rabbits, from the Institute for Experimental Animals, Kobe
University School of Medicine,17 were fed a standard chow diet supplemented with 0.5%
cholesterol (high cholesterol (HC)-diet,) for the duration of the experiment. Preliminary
experiments showed that severe atherosclerotic lesions developed by 45 days and that a PPS
dose of 30 mg/kg of body weight (BW) was the maximally tolerated dose without side
effects. A total of 20 rabbits were randomized into two groups after 45 days of the HC-diet.
For the next 30 days both groups were maintained on the HC-diet, but one group received
PPS (30 mg/kg BW daily) in the drinking water and the other received only tap water.
Hemoglobin levels remained unchanged and the feces remained guaiac negative. The rabbits
were killed by anesthesia with ketamine hydrochloride and xylazine (60 and 6 mg/kg BW,
respectively). Five per group were perfusion-fixed with 4% phosphate-buffered
formaldehyde solution. The remaining five per group were anesthetized, perfused with
saline, and aortic arch ring sections were snap-frozen in liquid nitrogen. Aortas were
removed from five additional untreated 4.5-month-old WHHL rabbits that had been fed the
HC-diet for 45 days, as baseline controls, and were similarly processed. Animal care and
procedures were in accordance with American Association for Accreditation for Laboratory
Animal Care and the National Institutes of Health guidelines.
Lupia et al. Page 2
Lab Invest. Author manuscript; available in PMC 2013 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Plasma Lipid and Lipoprotein Analyses
After a 12-h fast, blood was drawn into EDTA tubes at baseline, every 2 weeks, and at study
end. Total plasma cholesterol and triglyceride (Sigma), and unesterified cholesterol and
phospholipids were determined using enzymatic methods on a Hitachi 911 Autoanalyzer
(Boehringer Mannheim). Post-heparin hepatic lipase activity was determined as described.18
Morphological Analysis and Immunohistochemistry
Aortic atherosclerosis was evaluated as percent intimal lesion area (lesion surface area/entire
surface area) between the aortic arch origin and renal arteries. The intima-to-media ratio (I/
M ratio) was measured by computer-aided morphometric analysis in three consecutive
hematoxylin- and eosin-stained cross-sections: aortic arch, abdominal aorta, and origin of
the renal arteries. The thickest atherosclerotic lesions were selected for the analysis to avoid
errors due to the heterogeneity of lesions.19 The areas occupied by macrophages and
collagen were measured by computer-aided morphometry on sections stained with RAM-11
antibody (DAKO Corporation) or Sirius red.
Cell Preparation and Experimental Conditions
Human pro-monocytic U937 cells (5 ×106 cells per ml) in RPMI medium supplemented
with 10% FBS were stimulated with 10 ng/ml TNFα, in increasing concentrations of PPS
(10–100 μg/ml) or heparin (10–100 μg/ml), incubated at 37 °C for 3 h, and then in 0.1%
BSA-serum-free medium for 16–18 h. Supernatants were stored at −80 °C. Human
peripheral blood monocytes (PBMs) were isolated as described20 and maintained in medium
199 supplemented with 2% human serum for differentiation into macrophages.21
Peritoneal macrophages were used to assess the effect of in vivo treatment with PPS on
MMP activity. Before cell preparation, 12-week-old C57Bl/6J mice were treated with 100
mg/kg BW PPS orally (by gavage) for 5–6 days. Peritoneal macrophages were collected by
extensive washing of the peritoneal cavity with 0.1 BSA-RPMI medium 3 days after intra-
peritoneal injection of 1.5 ml thioglycollate, centrifuged at 200 g for 5 min, and suspended
at 0.2 ×106/ml in 10% FBS-RPMI in 24-well plate.21 Harvested macrophages were further
purified by adherence to plastic dishes for 2 h at 37 °C in 5% CO2, followed by three washes
with 0.1% BSA-RPMI medium, and then stimulated with TNFα as described above.
Zymography and Reverse Zymography
Briefly, aortic segments were homogenized, extracted in RIPA buffer, centrifuged, and
soluble extracts were harvested. For in vitro experiments, cell supernatants were normalized
for cell number. Aortic extracts and conditioned media, mixed with sample buffer, were
loaded onto a 10% gelatin poly-acrylamide gel.22 For reverse zymography, samples were
loaded onto a 15% gelatin polyacrylamide gel containing 0.5% porcine gelatin and 6 μg
recombinant gelatinase A.14
Evaluation of Net MMP Activity
MMP-2/MMP-9 net activity in aortic extracts was evaluated using a synthetic colorimetric
substrate (Ac-Pro-Leu-Gly-(2-mercapto-4-methylpentanoyl)-Leu-Gly-OEt; Calbiochem,
Cambridge, MA, USA). Recombinant gelatinase A and B were used as standards.
NF-κB Activity in RAW Cells
RAW cells (1 ×107 per dish) were treated with TNFα (10 ng/ml), with or without PPS (400
μg/ml) for 15, 30, or 60 min. Phosphorylated and total JNK, IκB, and p38 were determined
by western blots. The same membrane was re-probed with β-actin to ensure equal protein
loading. Experiments were repeated three times. The intensity of protein bands was
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quantitated by densitometry. NF-κB transcription activity was examined by transfecting
macrophages with an NF-κB luciferase reporter together with a β-gal plasmid using a
lipofectamine transfection kit from Promega, according to the manufacturer’s
recommendations. Controls included cells transfected with IKK and IκB to demonstrate that
NF-κB transcription was regulated by activators and suppressors, to verify that the assays
were functioning properly. TNFα was added to reporter-transfected cells together with or
without PPS. Experiments were repeated twice.
Statistical Analysis
Data are presented as mean±s.e.m. Differences among multiple groups were analyzed by
one-way analysis of variance (ANOVA) in combination with Bonferroni’s multiple
comparison test. Lipid levels were expressed as percent of the basal values for each
individual animal and analyzed by using repeated measures by ANOVA. Where appropriate,
statistical differences were assessed using Student’s t-test (Prism, GraphPad 3.02, San
Diego, CA, USA). A P-value of <0.05 was considered significant.
RESULTS
Progression of Established Atherosclerotic Lesions
The progression of established atherosclerosis induced by HC-diet in WHHL rabbits was
modestly, but significantly decreased by PPS treatment (Figure 1a and b). In the water-
treated controls, the aortic surface was irregular owing to the presence of multiple plaques of
varying size. In contrast, the aortic surface in the PPS-treated group was relatively smooth
and glistening and the plaques had a smooth flattened contour. Moreover, the aortic wall
was irregularly thickened and was less pliable in the water-treated group compared with the
PPS-treated group. Analysis of the intimal surface showed that the percent surface area of
the intima occupied by lesions in the PPS-treated group was reduced by approximately 10%
compared with the water-treated controls (Figure 1c). Microscopic examination of the aorta
in the PPS-treated group showed that the plaques were thinner and contained fewer foam
cells, no increase in the number of the cells in the intima or media, and a reduction in the I/
M ratio (Figure 1d and e). The calculated I/M ratio at the aortic arch and in the abdominal
aorta, close to the emergence of the renal arteries, was significantly increased from 45 to 75
days in WHHL rabbits fed an HC-diet (Figure 1f, black bars). The I/M ratio in PPS-treated
animals was significantly lower (Figure 1f, hatched bars) compared with untreated controls.
Moreover, the I/M ratio in rabbits fed an HC-diet for 45 days and treated with oral PPS for
an additional 30 days was not significantly different from that measured in WHHL rabbits
fed an HC-diet for 45 days (baseline), suggesting that the lesions did not progress during the
PPS treatment period (Figure 1f, white bars).
The plaques in the water-treated group contained a dense infiltrate of macrophages and
lacked a fibrous cap (Figure 2a and d). The plaques in the PPS-treated group had fewer
macrophages and were covered by an organized fibrous cap (Figure 2b and e). The plaque
area containing macrophages/total plaque area was decreased in PPS-treated rabbits
(36±2%) vs untreated controls (52±6%, P<0.05; Figure 2c).
Total collagen deposition within the atheroma, by Sirius red staining, showed significantly
more collagen in PPS-treated rabbits, especially on the luminal surface of plaques (47±3%)
vs controls (31±3%, P<0.01; Figure 2d–f).
Plasma Lipids
Rabbits on HC-diet for 45 days had increased plasma total (240±18%) and free (377±62%)
cholesterol, as well as phospholipid (221±33%) concentrations, while triglyceride
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concentrations decreased (36±9%) (Table 1). The levels were not further increased after an
additional 30 days on the atherogenic diet. There were no differences in lipid levels between
PPS- and water-treated animals (Table 1), although a trend towards a reduction of lipid
levels after PPS treatment was observed. Post-heparin hepatic lipase activity at the end of
treatment period revealed no differences between treatment groups (data not shown).
MMP and TIMP Activities in Aortic Extracts Ex Vivo
MMP activity was assessed in extracts of aortic arch ring sections snap-frozen in liquid
nitrogen using either a synthetic colorimetric substrate and by zymography. Net MMP-2/
MMP-9 activity, as assessed by a synthetic colorimetric substrate, was reduced in WHHL
rabbits treated with PPS compared with water-treated animals by 28±4% (P<0.05). MMP-2
activity, evaluated by zymography, was significantly increased in aortic extracts obtained
from PPS-treated WHHL rabbits (Figure 3a and b).
The activities of TIMPs, specific endogenous inhibitors of MMPs, were determined by
reverse zymography. The activities of TIMP-1, -2, and -3 after 75 days on the HC-diet did
not differ from those measured at 45 days (Figure 3c and d), whereas treatment with PPS
induced a marked increase in the activity of these TIMPs at 75 days (Figure 3c and d).
MMP Activity in Monocytes In Vitro and Ex Vivo
Since increased MMP activity in monocyte–macrophages may correlate with the
development of acute complications such as plaque rupture and thrombosis,5–11 we
evaluated the effect of PPS on MMP activity in U937 cells, human PBMs, and murine
peritoneal elicited macrophages by zymography. Unstimulated U937 cells expressed only
MMP-2 activity. However, after the addition of TNFα, they expressed both MMP-2 and
MMP-9 activities, which are characteristics of the in vitro macrophage phenotype (Figure
4a).23 PPS treatment decreased MMP-2 activity by 45±10% (P<0.01) in unstimulated U937
cells (Figure 4b), as did heparin treatment (Figure 4a). Both MMP-2 (38±12%; P<0.05) and
MMP-9 (52±11%; P<0.01) activities in U937 cells stimulated with 10 ng/ml TNFα (Figure
4a and c) were reduced by PPS treatment. The PPS effect was detectable at 25 μg/ml and
was maximal at 75–100 μg/ml (data not shown).
PPS inhibited MMP production by human PBMs after TNFα stimulation (Figure 4d–f). PPS
had no effect on cell viability, as assessed by Trypan blue staining (data not shown).
Murine peritoneal-elicited macrophages were used to assess the effect of in vivo treatment
with PPS on MMP activity. Peritoneal macrophages derived from mice treated orally with
PPS for the previous 5–6 days and stimulated in vitro with 10 ng/ml TNFα showed a
marked decrease in MMP-2 and MMP-9 activities, when compared with macrophages from
mice treated with water (Figure 4g), showing the efficacy in vivo of PPS treatment on MMP
activity.
TNFα-Induced NF-κB and MAPK Activation
Since the proinflammatory actions of TNFα are predominantly mediated by the NF-κB and
MAPK pathways, we examined the effects of PPS on TNFα-stimulated NF-κB and MAPK
activation. Treatment of RAW cells with TNFα quickly induced the phosphorylation of IκB,
JNK, and p38 (Figure 5a–d). The presence of PPS caused a ~50% reduction in TNFα-
stimulated IκB and p38 phosphorylation, while it had no significant effect on TNFα-
induced JNK phosphorylation. PPS decreased the stimulation of NF-κB transcription
activity by TNFα in a dose-dependent manner (Figure 5e).
Lupia et al. Page 5
Lab Invest. Author manuscript; available in PMC 2013 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DISCUSSION
This study shows that oral PPS prevents the progression of established atherosclerotic
lesions in aortas of WHHL rabbits fed a high-fat diet. This effect was not due to an
anticoagulant action, because PPS has only 1/15th the anticoagulant activity of heparin, and
bleeding was not observed. In addition, the reduction of atherosclerotic lesions after PPS
treatment did not appear to be related to changes in plasma lipid levels, as total and free
cholesterol, triglyceride, and phospholipid concentrations did not differ between PPS-treated
and control groups. Moreover, no difference in the activity of post-heparin hepatic lipase
was detected. In our study, we randomly divided the animals into two groups after 45 days
on the HC-diet, one received water and the other received PPS for the next 30 days. Plasma
lipids, analyzed separately after randomization, revealed that the values measured in the PPS
group at baseline as well as at 45 days showed a trend to be more elevated than in the
control group. We have no clear explanation for this issue; however, because also of small
numbers, we cannot exclude that the trend toward lower circulating lipoproteins seen in
PPS-treated animals after 75 days may also contribute to the anti-atherosclerotic effects
observed with PPS in vivo. Although we did not measure blood pressure in this study, others
have studied this is several different models and shown that PPS does not affect blood
pressure.13,24,25 Therefore, it is reasonable to conclude that the inhibition of atherosclerosis
progression induced by PPS treatment in WHHL rabbits is not mediated by a reduction of
blood pressure levels.
The use of heparin and heparin-like molecules has been previously proposed as a treatment
for atherosclerosis.1 However, the requirement for parenteral administration limits their use
for this indication, a limitation that does not apply to PPS. Oral PPS has been widely used
for treating interstitial cystitis.12 It has very few toxic side effects, even when administered
for prolonged periods of time.26 PPS treatment prevents the development of glomerular and
vascular lesions and tubulointerstitial inflammation and fibrosis in streptozotocin-induced
diabetes,27 bGH transgenic mice,27 and rats with cyclosporin A nephropathy28 or 5/6
nephrectomy,13 reduces the symptoms of inflammatory arthritis,29 and decreases infarct size
in an experimental myocardial ischemia/reperfusion injury model.30
The precise mechanism by which PPS achieves its protective effects has not been previously
elucidated. We found that atherosclerotic plaques in PPS-treated WHHL rabbits contained
fewer macrophages than those in water-treated controls. Others showed that PPS and
heparin inhibit activation of the complement cascade,31 binds or displaces inflammatory
cytokines,32 reduces NF-κB activation,33 scavenges free radicals,31 and reduces neutrophil
adhesion and infiltration.30 These mechanisms can directly contribute to reduced
macrophage recruitment and improved plaque development and stability.
We found that PPS treatment increased atherosclerotic plaque collagen content. As we have
previously shown that PPS modulates cell proliferation, and the synthesis and accumulation
of extracellular matrix,14,15,27 we focused on MMP and TIMP activities. Net MMP-2/
MMP-9 activity, evaluated using a synthetic colorimetric substrate, was significantly
decreased in aortic extracts of PPS-treated animals. Moreover, MMP-2 activity and TIMPs,
assessed by zymography and reverse zymography, respectively, were elevated in the aortic
wall of PPS-treated animals. MMP and TIMP activity have emerged as important
determinants of the atherosclerotic process and of vascular responses to injury.7–11
Increased amounts of several MMPs, including MMP-1, -3, -8, and -9, have been reported in
mouse and rabbit atherosclerotic plaques and in the rupture-prone shoulder region of human
atherosclerotic plaques.7–9,34,35 In particular, MMP-9 activity has been associated with the
presence of macrophages, a marker for plaques vulnerable to rupture, and is enhanced in
foam cells derived from the aortas of cholesterol-fed rabbits.7–11 In addition, adenovirus-
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mediated MMP-9 overexpression produced instability of advanced plaques in ApoE-null
mice,36 and the over-expression of a mutated fully-autoactivated form of MMP-9 in
macrophages induced high levels of plaque instability.37 However, not all MMPs are
markers for plaque inflammation; for instance, the levels of MMP-2 are increased in fibrous
rather than atheromatous human carotid plaques,35 and increased MMP-2 activity has been
associated mainly with smooth muscle cells and hence with plaque stability.35 Insights into
the role of MMPs and TIMPs have been obtained from transgenic and knockout studies
conducted in animal models of atherosclerosis. Although MMP-2-null mice show reduced
accumulation of vascular smooth muscle cells within plaques, suggesting less plaque
stability,38 genetic ablation of MMP-9 decreased plaque size, macrophage infiltration, and
elastin breaks.39 Conversely, systemic adenovirus-mediated gene transfer of TIMP-1 or
TIMP-2 improved plaque stability40,41 and prevented the progression of established
brachiocephalic artery plaques.40 Moreover, TIMP-1-null mice showed increased
macrophage intra-plaque infiltration and higher destruction of medial elastin layers.42,43
Taken together, these results are consistent with the hypothesis of different roles of the
various MMPs in the pathogenesis of atherosclerotic plaque progression. Some MMPs, in
particular MMP-2, favor smooth muscle cell migration and fibrous cap formation, thus
promoting plaque stability. Whereas others, including activated MMP-9, are involved in
matrix degradation or enhancement of intra-plaque inflammation, factors that are associated
with plaque rupture. Herein, we found that reduced progression of atherosclerotic lesions in
the aortas of PPS-treated WHHL rabbits is associated with decreased net collagenolytic
activity and increased MMP-2 and TIMP activities within the aortic wall. These findings are
consistent with the conclusion that increased collagen deposition is a feature accompanying
reduced progression of atherosclerotic lesions induced by PPS treatment. This suggests that
PPS-induced MMP-2 and TIMP overexpression within the plaque may contribute to plaque
stabilization.
Previous reports correlated increased MMP activity by monocyte–macrophages to the
development of acute complications such as plaque rupture and thrombosis.5–10,33 We found
that PPS inhibited both MMP-2 and MMP-9 enzymatic activities in two types of human
monocytes, a pro-monocytic cell line (U937 cells) and PBMs from normal volunteers. To
further confirm this hypothesis, we studied MMP activity in elicited peritoneal macrophages
derived from mice treated orally with PPS. In these animals, TNFα-stimulated MMP
activity was significantly decreased after PPS treatment compared with control animals,
suggesting that this mechanism may be present in vivo. As the concentrations used for the in
vitro experiments were close to the plasma levels reached in vivo after oral administration of
PPS,27 this compound may have therapeutic use in humans in these disease processes.
Moreover, the inhibitory activity of PPS on MMPs was still significant when the drug was
administered up to 3 h after TNFα stimulation.
It has been previously shown that inflammatory mediators, such as TNFα, play an active
role in atherosclerosis progression. An important mechanism by which TNFα increases
inflammation is via upregulation of proinflammatory genes in macrophages.44 Since we
found that PPS suppressed TNFα-stimulated IκB phosphorylation, NF-κB transcription, and
p38 phosphorylation, it is possible that PPS may directly decrease TNFα-induced NF-κB
and AP-1 activities. The finding that PPS decreases TNFα-stimulated iNOS, MCP-1,
ICAM-1, and CXCL-1 mRNA expression in renal proximal tubular cells and podocytes via
the inhibition of NF-κB indirectly supports this reasoning.
Thus, the beneficial effects of PPS on established atherosclerotic lesions may include
stabilization of the amount of collagen in plaques mediated by modulation of MMP and
TIMP activities, reduction of macrophage infiltration into the atherosclerotic plaque, and
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inhibition of inflammation in monocytes/macrophages exemplified by decreased MMP
activity, NF-κB activation, and p38 phosphorylation.
PPS also reduces binding of acetylated low-density lipoproteins to endothelial cells,45 and
selectively inactivates several heparin-binding growth factors.46 Furthermore, PPS is both
negatively charged and hydrophilic, two properties promoting its localization to the
endothelial cell surface and preservation of the glycocalyx ‘shield’.31
In conclusion, we showed that the oral administration of PPS treatment retards the
progression of established atherosclerosis in WHHL rabbits. The PPS effect appeared to be
related to its ability to reduce inflammation, including macrophage infiltration and to
regulate MMP and TIMP activities within the wall of the atherosclerotic aorta in a manner
that favors collagen deposition, rather than collagen degradation. These properties may
promote plaque stability. PPS treatment increased MMP-2 and TIMP activities within the
atherosclerotic plaque, while it inhibited MMP-2 and MMP-9 activities in monocytes/
macrophages. Further studies are required to assess the relevance of these observations to
treatment of patients with established atherosclerosis.
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Figure 1.
Analysis of atherosclerotic lesions in Watanabe heritable hyperlipidemic (WHHL) rabbits.
Animals were fed a high-cholesterol (HC)-diet for 75 days. After 45 days, they were
randomized into two groups, one receiving pentosan polysulfate (PPS) (30 mg/kg body
weight (BW) daily) in the drinking water and the other receiving tap water only, as detailed
in the Materials and Methods section. (a and b) Representative photographs of aortic inner
surface after 75 days of an HC-diet. Images were obtained from aortas freshly dissected
from rabbits perfusion-fixed with 4% phosphate-buffered formaldehyde solution (five per
group). (a) HC-diet for 75 days plus tap water. (b) HC-diet for 75 days, and on day 45, PPS
was added to the drinking water and continued for the remaining 30 days. (c) Quantification
of atherosclerotic lesions in WHHL rabbits by en face analysis in WHHL rabbits. Aortic
atherosclerosis was evaluated as percent intimal lesion area (lesion surface area/entire
surface area) between the aortic arch origin and renal arteries. *P<0.05. (d and e)
Representative photographs of hematoxylin- and eosin-stained cross-sections of aortic arch
obtained from WHHL rabbits after 75 days on an HC-diet. Aortic arch cross-sections were
obtained from aortas freshly dissected from rabbits perfusion-fixed with 4% phosphate-
buffered formaldehyde solution (five per group). (d) HC-diet for 75 days plus tap water. (e)
HC-diet for 75 days, and on day 45, PPS was added to the drinking water and continued for
the remaining 30 days. (f) Intima-to-media (I/M) ratio of aortic cross-sections. The I/M ratio
was measured by computer-aided morphometric analysis in the aortic arch and near the
origin of the renal arteries. *P<0.05, **P<0.01.
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Figure 2.
Analysis of macrophage infiltration and collagen content in atherosclerotic lesions from
Watanabe heritable hyperlipidemic (WHHL) rabbits. Animals were fed a high cholesterol
(HC)-diet for 75 days. After 45 days, they were randomized into two groups, one receiving
pentosan polysulfate (PPS) (30 mg/kg body weight (BW) daily) in the drinking water and
the other receiving tap water only, as detailed in the Materials and Methods section. (a and
b) Representative micrographs of aortic arch cross-sections stained with RAM-11 antibody
to detect infiltrating macrophages. (a) HC-diet for 75 days. (b) HC-diet for 75 days, and on
day 45, PPS was added and continued for the remaining 30 days. (c) Quantification of the
area occupied by macrophages as measured by computer-aided morphometry in aortic arch
cross-sections stained with RAM-11 antibody. (d and e) Representative micrographs of
aortic arch cross-sections stained with Sirius red to identify collagen. (d) HC-diet for 75
days. (e) HC-diet for 75 days, and on day 45, PPS was added and continued for the
remaining 30 days. (f) Quantification of the area occupied by collagen as measured by
computer-aided morphometry in aortic arch cross-sections stained with Sirius red. *P<0.05.
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Figure 3.
Matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP)
levels in aortic extracts from Watanabe heritable hyperlipidemic (WHHL) rabbits. WHHL
rabbits were fed a high cholesterol (HC)-diet for 75 days. After 45 days, they were
randomized into two groups, one receiving pentosan polysulfate (PPS) (30 mg/kg body
weight (BW) daily) in the drinking water and the other receiving tap water only, as detailed
in the Materials and Methods section. After 75 days, five animals per group were
anesthetized, perfused with saline, and aortic arch ring sections were snap-frozen in liquid
nitrogen. Aortas were removed from five additional untreated 4.5-month-old WHHL rabbits
that had been fed the HC-diet for 45 days, as baseline controls. (a) Representative
zymography of aortic extracts obtained from WHHL rabbits on an HC-diet. (b)
Quantification of MMP-2 activity by densitometric analysis in aortic extracts obtained from
WHHL rabbits on an HC-diet (n =3 experiments, *P<0.05). (c) Representative reverse
zymographic analysis of TIMPs in aortic extracts obtained from WHHL rabbits on an HC-
diet. (d) Quantification of TIMP levels by densitometric analysis in aortic extracts obtained
from WHHL rabbits on an HC-diet (n =3 experiments, *P<0.05, **P<0.01).
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Figure 4.
Matrix metalloproteinase (MMP) activity in monocytes–macrophages. Human pro-
monocytic U937 cells or human peripheral blood-derived monocytes (PBMs) in RPMI
medium supplemented with 10% fetal bovine serum (FBS) were stimulated with 10 ng/ml
tumor necrosis factor α (TNFα), in the presence or absence of pentosan polysulfate (PPS)
(100 μg/ml) or heparin (100 μg/ml), incubated at 37 °C for 3 h, and then in 0.1% bovine
serum albumin (BSA)-serum-free medium for 16–18 h, as detailed in the Materials and
Methods section. (a) Representative zymographic analysis of U937 cell supernatants. (b)
MMP-2 activity was quantified by densitometry in supernatants of unstimulated U937 cells.
Open bar, no treatment; filled bar, treatment with 100 μg/ml PPS. Data are expressed as the
percent of control (unstimulated U937 cells). Shown are mean±s.e.m. of five independent
experiments. **P<0.01. (c) MMP-2 and MMP-9 activities were quantified by densitometry
in supernatants of U937 cells stimulated with 10 ng/ml TNFα. Open bar, no treatment; filled
bar, treatment with 100 μg/ml PPS. Data are expressed as the percent of control (10 ng/ml
TNFα-stimulated U937 cells). Shown are mean±s.e.m. of five independent experiments.
*P<0.05, **P<0.01. (d) Representative zymographic analysis of supernatants from human
PBMs. (e) Quantification of MMP-2 and MMP-9 activities by densitometric analysis in the
supernatants of unstimulated human PBMs, in the absence (open bars) or presence (filled
bars) of 100 μg/ml PPS, expressed as the percent of control (unstimulated human PBMs).
Shown are mean±s.e.m. of three independent experiments. *P<0.05, **P<0.01. (f) MMP-2
and MMP-9 activities were quantified by densitometry in the supernatants of human PBMs
stimulated with 10 ng/ml TNFα, in the absence (open bars) or presence (filled bars) of 100
μg/ml PPS, expressed as the percent of control (10 ng/ml TNFα-stimulated human PBMs).
(g) Effect of in vivo treatment with PPS on MMP activity in murine peritoneal-elicited
macrophages: representative zymographic analysis of supernatants from peritoneal
macrophages derived from mice treated orally with PPS (100 mg/kg body weight (BW)) for
the previous 5–6 days and stimulated in vitro with 10 ng/ml TNFα, compared with
macrophages from mice treated with water (Control).
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Figure 5.
Modulation of mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB)
activation in RAW cells. (a) RAW cells were treated with tumor necrosis factor α (TNFα)
(10 ng/ml) in the presence or absence of pentosan polysulfate (PPS) (400 μg/ml) and
phosphorylated, and total JNK, IκB, and p38 levels were determined by western blots. The
same membranes were probed with β-actin to assess protein loading. Relative expression of
p-JNK, p-IκB, p-p38 to β-actin (b–d, respectively; #P<0.05 vs TNFα 15 min; *P<0.05 vs
TNFα 30 min; ¶P<0.05 vs TNFα 60 min). (d) NF-κB transcription activity was examined
by transfecting macrophages with an NF-κB luciferase reporter together with a β-gal
plasmid. Controls included cells transfected with IKK (dashed column) and IκB (white
column). TNFα (10 ng/ml) was added to reporter-transfected cells together with or without
increasing concentrations (100–400 μg/ml) of PPS.
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Table 1
Plasma lipid concentrations
Baseline 45 days HC-diet 75 days HC-diet
Total cholesterol (mg/dl)
 Control (water-treated) 846±68 1979±78 1894±57
 PPS-treated 901±50 2133±85 1565±212
Free cholesterol (mg/dl)
 Control (water-treated) 251±22 963±127 967±93
 PPS-treated 283±13 1039±129 785±93
Triglycerides (mg/dl)
 Control (water-treated) 750±120 238±610 275±69
 PPS-treated 763±72 331±87 184±30
Phospholipids (mg/dl)
 Control (water-treated) 504±42 1118±130 1070±102
 PPS-treated 575±26 1241±143 878±108
Abbreviations: PPS, Pentosane polysulfate; WHHL, Watanabe heritable hyper-lipidemic; BW, body weight.
Plasma lipid levels were measured at baseline (3 months of age) and after 45 and 75 days on a high cholesterol (HC)-diet. After 45 days on an HC-
diet, WHHL rabbits were randomized to receive tap water (Control) or PPS (30 μg/kg BW daily) added to the drinking water for the next 30 days,
as detailed in the Materials and Methods section. Data are expressed as mg/dl, mean±s.e.m. of five animals in each group.
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